Global Calming Aids for Dogs Market Strategic Research Report
By Type: Calming Supplements, Pheromone Sprays, Calming Collars, Anxiety Vests
By Application: Household, Pet Hospitals and Clinics, Pet Shop, Others
Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America
Key Players: VetriScience, H&H Group, Vetoquinol, ThunderEase, Maxxidog, Heavenly Hounds, ElleVet Sciences, Wild One, FOMO Bones, Ark Naturals, Purina, Kradle, Zoetis, Pet Remedy, Ceva, Adaptil, Primo Pup, Penelope's Bloom, Extract Labs, Koi CBD, Elanco, Zatural, The Anxious Pet, This Dog's Life, NaturVet, King Kanine, Dr. Harvey’s, PetHonesty, Merck Animal Health, Boehringer Ingelheim, Shangrao Chunyu Technology, Shandong Youmi Le Health Technology
نظرة عامة
Scope of the Report
The global Calming Aids for Dogs market size is predicted to grow from US$ 556 million in 2025 to US$ 890 million in 2032; it is expected to grow at a CAGR of 7.1% from 2026 to 2032.
Canine sedatives refer to a class of drugs specifically used for canines, which are intended to calm, soothe or reduce anxiety through drug effects. Such drugs are usually used in veterinary clinical practice to help dogs stay calm during surgery, examination, treatment or specific stressful situations (such as travel, thunderstorm phobia, separation anxiety, etc.), reduce tension, fear or aggressive behavior, thereby ensuring the smooth progress of medical operations or improving animal welfare.
The market for canine sedatives has shown a steady growth trend in recent years, mainly benefiting from the booming pet economy and the significant increase in pet owners' attention to pet health and welfare. With the acceleration of urbanization and the improvement of people's living standards, the number of pet-raising families is increasing. As one of the most common pets, dogs have increasingly diversified medical needs, especially the use of sedatives, including surgical anesthesia assistance, behavior correction, travel comfort, etc. Current market dynamics show that technological innovation is the key to driving the development of the industry. The research and development of new sedatives focuses on safer, more efficient, and low-side effect products, such as drugs based on natural ingredients or targeted mechanisms of action, to meet the market's demand for pet-friendly medical solutions. At the same time, the strengthening of regulatory supervision has prompted companies to pay more attention to product quality and compliance, while the expansion of online sales channels and the digital transformation of pet medical services have also brought new growth points to the dog sedative market. It is expected that in the next few years, with the continued expansion of the pet medical market and the deepening of consumer awareness, the dog sedative market will maintain steady growth and develop in a more professional and refined direction.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Calming Aids for Dogs market?
What factors are driving Calming Aids for Dogs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Calming Aids for Dogs market opportunities vary by end market size?
How does Calming Aids for Dogs break out by Type, by Application?
This report presents a comprehensive overview of the global Calming Aids for Dogs market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.
Segment by Type
- Calming Supplements
- Pheromone Sprays
- Calming Collars
- Anxiety Vests
Segment by Application
- Household
- Pet Hospitals and Clinics
- Pet Shop
- Others
Who Can Use This Report?
This report is written for decision-makers who need a clear, data-backed view of the global Calming Aids for Dogs market:
- Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
- Distributors, channel partners and end users in Household, Pet Hospitals and Clinics, Pet Shop evaluating demand and sourcing options
- Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
- Government agencies, industry associations and research institutions tracking industry developments and policy impact
Market snapshot
Global Calming Aids for Dogs Market Strategic Research Report snapshot, 2025–2032
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.Segments covered in this report
Table of contents
01Executive Summary
02Industry Overview & Forecast
- 2.1.1 Market Definition and Scope
- 2.1.2 Market Size and Growth Forecast
- 2.1.3 Volume Analysis
- 2.1.4 Segment Outlook by Type
- 2.1.5 Segment Outlook by Application
- 2.1.6 Regional Outlook
- 2.1.7 Structural Developments Shaping the Forecast
- 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
- 3.1 Market Segmentation by Type
- 3.1.1 Market by Type Overview
- 3.1.2 Calming Supplements
- 3.1.3 Pheromone Sprays
- 3.1.4 Calming Collars
- 3.1.5 Anxiety Vests
- 3.1.6 Volume Analysis
04Market Segmentation by Application
- 4.1 Market Segmentation by Application
- 4.1.1 Market by Application Overview
- 4.1.2 Household
- 4.1.3 Pet Hospitals and Clinics
- 4.1.4 Pet Shop
- 4.1.5 Others
- 4.1.6 Volume Analysis
05Regional Market Forecast
- Asia Pacific
- North America
- Europe
- Middle East & Africa
- Latin America
06Country-Level Market Forecast
- 6.1 Asia Pacific
- 6.1.1 China
- 6.1.2 Japan
- 6.1.3 Korea
- 6.1.4 Southeast Asia
- 6.1.5 India
- 6.1.6 Australia
- 6.1.7 Rest of Asia Pacific
- 6.2 North America
- 6.2.1 United States
- 6.2.2 Canada
- 6.2.3 Mexico
- 6.2.4 Rest of North America
- 6.3 Europe
- 6.3.1 Germany
- 6.3.2 France
- 6.3.3 UK
- 6.3.4 Italy
- 6.3.5 Russia
- 6.3.6 Rest of Europe
- 6.4 Middle East & Africa
- 6.4.1 Egypt
- 6.4.2 South Africa
- 6.4.3 Israel
- 6.4.4 Turkey
- 6.4.5 GCC Countries
- 6.4.6 Rest of Middle East & Africa
- 6.5 Latin America
- 6.5.1 Brazil
- 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
- 7.1 Growth Drivers & Inhibitors
- 7.1.1 Section Overview
- 7.1.2 Growth Drivers
- 7.1.3 Growth Inhibitors
- 7.1.4 Driver and Inhibitor Impact Assessment
- 7.1.5 Analyst Perspective
08Key Company Profiles
- 8.1 VetriScience
- 8.1.1 Company Overview
- 8.1.2 Key Products & Segments
- 8.1.3 Financial Performance (2023–2025)
- 8.1.4 Business Strategy
- 8.1.5 SWOT Analysis
- 8.1.6 Strategic Implications (2026–2032)
- 8.2 H&H Group
- 8.2.1 Company Overview
- 8.2.2 Key Products & Segments
- 8.2.3 Financial Performance (2023–2025)
- 8.2.4 Business Strategy
- 8.2.5 SWOT Analysis
- 8.2.6 Strategic Implications (2026–2032)
- 8.3 Vetoquinol
- 8.3.1 Company Overview
- 8.3.2 Key Products & Segments
- 8.3.3 Financial Performance (2023–2025)
- 8.3.4 Business Strategy
- 8.3.5 SWOT Analysis
- 8.3.6 Strategic Implications (2026–2032)
- 8.4 ThunderEase
- 8.4.1 Company Overview
- 8.4.2 Key Products & Segments
- 8.4.3 Financial Performance (2023–2025)
- 8.4.4 Business Strategy
- 8.4.5 SWOT Analysis
- 8.4.6 Strategic Implications (2026–2032)
- 8.5 Maxxidog
- 8.5.1 Company Overview
- 8.5.2 Key Products & Segments
- 8.5.3 Financial Performance (2023–2025)
- 8.5.4 Business Strategy
- 8.5.5 SWOT Analysis
- 8.5.6 Strategic Implications (2026–2032)
- 8.6 Heavenly Hounds
- 8.6.1 Company Overview
- 8.6.2 Key Products & Segments
- 8.6.3 Financial Performance (2023–2025)
- 8.6.4 Business Strategy
- 8.6.5 SWOT Analysis
- 8.6.6 Strategic Implications (2026–2032)
- 8.7 ElleVet Sciences
- 8.7.1 Company Overview
- 8.7.2 Key Products & Segments
- 8.7.3 Financial Performance (2023–2025)
- 8.7.4 Business Strategy
- 8.7.5 SWOT Analysis
- 8.7.6 Strategic Implications (2026–2032)
- 8.8 Wild One
- 8.8.1 Company Overview
- 8.8.2 Key Products & Segments
- 8.8.3 Financial Performance (2023–2025)
- 8.8.4 Business Strategy
- 8.8.5 SWOT Analysis
- 8.8.6 Strategic Implications (2026–2032)
- 8.9 FOMO Bones
- 8.9.1 Company Overview
- 8.9.2 Key Products & Segments
- 8.9.3 Financial Performance (2023–2025)
- 8.9.4 Business Strategy
- 8.9.5 SWOT Analysis
- 8.9.6 Strategic Implications (2026–2032)
- 8.10 Ark Naturals
- 8.10.1 Company Overview
- 8.10.2 Key Products & Segments
- 8.10.3 Financial Performance (2023–2025)
- 8.10.4 Business Strategy
- 8.10.5 SWOT Analysis
- 8.10.6 Strategic Implications (2026–2032)
- 8.11 Purina
- 8.11.1 Company Overview
- 8.11.2 Key Products & Segments
- 8.11.3 Financial Performance (2023–2025)
- 8.11.4 Business Strategy
- 8.11.5 SWOT Analysis
- 8.11.6 Strategic Implications (2026–2032)
- 8.12 Kradle
- 8.12.1 Company Overview
- 8.12.2 Key Products & Segments
- 8.12.3 Financial Performance (2023–2025)
- 8.12.4 Business Strategy
- 8.12.5 SWOT Analysis
- 8.12.6 Strategic Implications (2026–2032)
- 8.13 Zoetis
- 8.13.1 Company Overview
- 8.13.2 Key Products & Segments
- 8.13.3 Financial Performance (2023–2025)
- 8.13.4 Business Strategy
- 8.13.5 SWOT Analysis
- 8.13.6 Strategic Implications (2026–2032)
- 8.14 Pet Remedy
- 8.14.1 Company Overview
- 8.14.2 Key Products & Segments
- 8.14.3 Financial Performance (2023–2025)
- 8.14.4 Business Strategy
- 8.14.5 SWOT Analysis
- 8.14.6 Strategic Implications (2026–2032)
- 8.15 Ceva
- 8.15.1 Company Overview
- 8.15.2 Key Products & Segments
- 8.15.3 Financial Performance (2023–2025)
- 8.15.4 Business Strategy
- 8.15.5 SWOT Analysis
- 8.15.6 Strategic Implications (2026–2032)
- 8.16 Adaptil
- 8.16.1 Company Overview
- 8.16.2 Key Products & Segments
- 8.16.3 Financial Performance (2023–2025)
- 8.16.4 Business Strategy
- 8.16.5 SWOT Analysis
- 8.16.6 Strategic Implications (2026–2032)
- 8.17 Primo Pup
- 8.17.1 Company Overview
- 8.17.2 Key Products & Segments
- 8.17.3 Financial Performance (2023–2025)
- 8.17.4 Business Strategy
- 8.17.5 SWOT Analysis
- 8.17.6 Strategic Implications (2026–2032)
- 8.18 Penelope's Bloom
- 8.18.1 Company Overview
- 8.18.2 Key Products & Segments
- 8.18.3 Financial Performance (2023–2025)
- 8.18.4 Business Strategy
- 8.18.5 SWOT Analysis
- 8.18.6 Strategic Implications (2026–2032)
- 8.19 Extract Labs
- 8.19.1 Company Overview
- 8.19.2 Key Products & Segments
- 8.19.3 Financial Performance (2023–2025)
- 8.19.4 Business Strategy
- 8.19.5 SWOT Analysis
- 8.19.6 Strategic Implications (2026–2032)
- 8.20 Koi CBD
- 8.20.1 Company Overview
- 8.20.2 Key Products & Segments
- 8.20.3 Financial Performance (2023–2025)
- 8.20.4 Business Strategy
- 8.20.5 SWOT Analysis
- 8.20.6 Strategic Implications (2026–2032)
- 8.21 Elanco
- 8.21.1 Company Overview
- 8.21.2 Key Products & Segments
- 8.21.3 Financial Performance (2023–2025)
- 8.21.4 Business Strategy
- 8.21.5 SWOT Analysis
- 8.21.6 Strategic Implications (2026–2032)
- 8.22 Zatural
- 8.22.1 Company Overview
- 8.22.2 Key Products & Segments
- 8.22.3 Financial Performance (2023–2025)
- 8.22.4 Business Strategy
- 8.22.5 SWOT Analysis
- 8.22.6 Strategic Implications (2026–2032)
- 8.23 The Anxious Pet
- 8.23.1 Company Overview
- 8.23.2 Key Products & Segments
- 8.23.3 Financial Performance (2023–2025)
- 8.23.4 Business Strategy
- 8.23.5 SWOT Analysis
- 8.23.6 Strategic Implications (2026–2032)
- 8.24 This Dog's Life
- 8.24.1 Company Overview
- 8.24.2 Key Products & Segments
- 8.24.3 Financial Performance (2023–2025)
- 8.24.4 Business Strategy
- 8.24.5 SWOT Analysis
- 8.24.6 Strategic Implications (2026–2032)
- 8.25 NaturVet
- 8.25.1 Company Overview
- 8.25.2 Key Products & Segments
- 8.25.3 Financial Performance (2023–2025)
- 8.25.4 Business Strategy
- 8.25.5 SWOT Analysis
- 8.25.6 Strategic Implications (2026–2032)
- 8.26 King Kanine
- 8.26.1 Company Overview
- 8.26.2 Key Products & Segments
- 8.26.3 Financial Performance (2023–2025)
- 8.26.4 Business Strategy
- 8.26.5 SWOT Analysis
- 8.26.6 Strategic Implications (2026–2032)
- 8.27 Dr. Harvey’s
- 8.27.1 Company Overview
- 8.27.2 Key Products & Segments
- 8.27.3 Financial Performance (2023–2025)
- 8.27.4 Business Strategy
- 8.27.5 SWOT Analysis
- 8.27.6 Strategic Implications (2026–2032)
- 8.28 PetHonesty
- 8.28.1 Company Overview
- 8.28.2 Key Products & Segments
- 8.28.3 Financial Performance (2023–2025)
- 8.28.4 Business Strategy
- 8.28.5 SWOT Analysis
- 8.28.6 Strategic Implications (2026–2032)
- 8.29 Merck Animal Health
- 8.29.1 Company Overview
- 8.29.2 Key Products & Segments
- 8.29.3 Financial Performance (2023–2025)
- 8.29.4 Business Strategy
- 8.29.5 SWOT Analysis
- 8.29.6 Strategic Implications (2026–2032)
- 8.30 Boehringer Ingelheim
- 8.30.1 Company Overview
- 8.30.2 Key Products & Segments
- 8.30.3 Financial Performance (2023–2025)
- 8.30.4 Business Strategy
- 8.30.5 SWOT Analysis
- 8.30.6 Strategic Implications (2026–2032)
- 8.31 Shangrao Chunyu Technology
- 8.31.1 Company Overview
- 8.31.2 Key Products & Segments
- 8.31.3 Financial Performance (2023–2025)
- 8.31.4 Business Strategy
- 8.31.5 SWOT Analysis
- 8.31.6 Strategic Implications (2026–2032)
- 8.32 Shandong Youmi Le Health Technology
- 8.32.1 Company Overview
- 8.32.2 Key Products & Segments
- 8.32.3 Financial Performance (2023–2025)
- 8.32.4 Business Strategy
- 8.32.5 SWOT Analysis
- 8.32.6 Strategic Implications (2026–2032)
09Competitive Landscape
- 9.1 Competitive Landscape Overview
- 9.2 Competitive Intensity Assessment
- 9.3 Key Player Strategies & Positioning
- 9.4 Competitive Dynamics & Strategic Outlook
- 9.4.1 Emerging Competitive Threats
- 9.4.2 Consolidation vs. Fragmentation Outlook
- 9.4.3 Competitive Response Matrix
- 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
- 10.1 Threat of New Entrants
- 10.2 Bargaining Power of Buyers
- 10.3 Bargaining Power of Suppliers
- 10.4 Threat of Substitutes
- 10.5 Competitive Rivalry
11PESTLE Analysis
- 11.1 Political
- 11.2 Economic
- 11.3 Social and Demographic
- 11.4 Technological
- 11.5 Legal and Regulatory
- 11.6 Environmental
- 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
- 13.1 Future Trends & Outlook
- 13.1.1 Trend Summary and Commercial Maturity Assessment
- 13.1.2 Technology and Innovation Trends
- 13.1.3 Long-Term Market Outlook
- 13.1.4 Investment & M&A Activity Outlook
- 13.1.5 Overall Outlook Assessment
Frequently asked questions
What is the size of the global Calming Aids for Dogs market?
What is the forecast CAGR for the Calming Aids for Dogs market?
What is Calming Aids for Dogs?
What are the main segments of the Calming Aids for Dogs market by type?
Which applications drive demand in the Calming Aids for Dogs market?
Who are the key players in the Calming Aids for Dogs market?
Which regions and countries are covered for Calming Aids for Dogs?
What is driving growth in the Calming Aids for Dogs market?
Who should buy the Calming Aids for Dogs market report?
What license options are available for this report?
Research Methodology
All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.
Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.
Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.
Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.
CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.
All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.
On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.
Need a customized version?
Get country-, segment- or company-specific intelligence tailored to your exact requirements.
Request custom research →Request a free sample
Receive a sample of Global Calming Aids for Dogs Market Strategic Research Report before you buy.
Customize This Report
Describe your specific requirements and our analysts will scope and deliver a tailored version.
Request Invoice
We will email a proforma invoice within 24 hours. Report access is granted upon payment confirmation.
Navadhi Market Research · Pharmaceuticals